## 510(K) SUMMARY FOR THE INNOVA CORPORATION SCALLOPED ENDOPORE IMPLANT

## DEC 1 4 2004

## Submitter's Name, Address, Telephone Number, And Contact Person

Innova LifeSciences Corporation 525 University Avenue, Suite 777 Toronto, Ontario M5G 2L3 Canada

Contact:

Michael A. Kehoe, President

Telephone: (416) 340-8818

Facsimile:

(416) 340-0415

### Date Prepared

November 12, 2004

#### Name of the Device

Scalloped Endopore® Endosseous Dental Implant System

### Common or Usual Name

**Endosseous Implant and Abutment** 

#### Classification Name

Endosseous Implant (DZE); Endosseous Dental Implant Abutment (NHA)

#### Predicate Devices

Endopore® Endosseous Dental Implant System in 4.1 mm diameter (K926354) and 5.0 mm diameter (K971196); 5 mm long x 5.0 mm diameter Endopore Endosseous Dental Implant System (K032140).

#### **Intended Use**

The Endopore Implant is indicated for use in the upper or lower jaw arches to provide support for a dental prosthesis.

**Principles of Operation** 

K043190

The principles of operation of the modified device are identical to the previously cleared Endopore Implant System except for the attachment of abutments via an internal connection.

## **Technological Characteristics**

The technological characteristics of the modified Scalloped Endopore Implant also are identical to the predicates, except for the addition of a 1.5 mm lightly-acid etched region immediately apical to the smooth coronal region, and a scalloped coronal margin. The dimensions of the modified Scalloped Endopore Implant, 10.5 mm in length x 4.8 mm diameter, are within the range of the dimensions of previously cleared Endopore implants.

## Summary Basis for the Finding of Substantial Equivalence

The minor modification to the surface of the Endopore Implant does not alter its indications for use or its fundamental scientific technology. Therefore, the modified device is substantially equivalent to the predicates.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## DEC 1 4 2004

Mr. Howard M. Holstein Innova LifeSciences Corporation 555 Thirteenth Street, NW Washington, DC 20004-1109

Re: K043190

Trade/Device Name: Scalloped Endopore Endosseous Dental Implant System

Regulation Number: 872.3640

Regulation Name: Endosseous Implant

Regulatory Class: II Product Code: NHA

Dated: December 10, 2004 Received: December 10, 2004

#### Dear Mr. Holstein:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal</u> Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and

Radiological Health

Enclosure

# **Indications for Use**

510(k) Number (if known): KOH3190
Device Name: Scalloped Endopore® Endosseous Dental Implant System
Indications For Use:
For use as an endosseous dental implant in the upper or lower jaw arches to provide support for prosthetic devices.
Prescription Use X AND/OR Over-The-Counter Use (21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off) (Division of Anesthesiology, General Hospital, Division of Anesthesiology, Devices Infection Control, Dental Devices (VOY3) F1() Page 1 of 1
Infection Control, Box 1043 P10 Page 1 of 1